ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2022
Characteristics of subjective cognitive decline associated with amyloid positivity.
Abstract read
In one paragraph
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- APOE in subjective cognitive decline: a systematic review and meta-analysis.Journal of neurology · 2026Pooled it
- SCD-plus features and AD biomarkers in cognitively unimpaired samples: A meta-analytic approach for nine cohort studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Beneficial Effect of Societal Factors on APOE-ε2 and ε4 Carriers' Brain Health: A Systematic Review.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Pooled it
- Association of amyloid-beta with depression or depressive symptoms in older adults without dementia: a systematic review and meta-analysis.Translational psychiatry · 2024Pooled it
- Depression and anxiety modify cognitive concerns associated with amyloid and early clinical impairment.Neuropsychology · 2026Article
- Unmasking preclinical Alzheimer's pathology: auditory distraction cost and occupational reserve jointly discriminate amyloid positivity in subjective cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Trajectories of Self-Awareness Across the Alzheimer's Disease Spectrum: A Systematic Review of Its Potential Contribution to Early Diagnosis.Diagnostics (Basel, Switzerland) · 2026Review
- The predictive role of olfactory identification on episodic memory and mild cognitive impairment: Results from the CIMA-Q cohort.Journal of Alzheimer's disease : JAD · 2026Article
- Assessing outer retinal and choroidal changes in scd: potential for high-risk screening using SS-OCTA.Translational psychiatry · 2025Article
- Disentangling Neurodegeneration with Brain Age Gap Prediction Models: A Graph Signal Processing Perspective.ArXiv · 2025Article
- Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer´s disease.Molecular psychiatry · 2025Article
- Research progress on brain network imaging biomarkers of subjective cognitive decline.Frontiers in neuroscience · 2025Review
- Factors affecting subjective cognitive decline: an automated machine learning approach.Frontiers in neuroscience · 2025Article
- Sex-Specific Entorhinal Cortex Functional Connectivity in Cognitively Normal Older Adults with Amyloid-β Pathology.Molecular neurobiology · 2025Article
- Longitudinal associations between amyloid and symptoms of depression and anxiety in subjective cognitive decline: the impact of personality characteristics.Frontiers in psychiatry · 2025Article
- Odor induced functional connectivity alteration of POC-anterior frontal cortex-medial temporal cortex in patients with mild cognitive impairment.Frontiers in aging neuroscience · 2025Article
- Single-value brain activity scores reflect both severity and risk across the Alzheimer's continuum.Brain : a journal of neurology · 2024Article
- Inequalities in accelerated cognitive decline: Resolving observational window bias using nested non-linear regression.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Clinical predictors of Alzheimer's disease-like brain atrophy in individuals with memory complaints.Brain and behavior · 2024Article
- Subjective Cognitive Decline and Genetic Propensity for Dementia beyond Apolipoprotein εCurrent issues in molecular biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
64 authors.
Olin JanssenAlzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Willemijn J JansenAlzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Stephanie J B VosAlzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Merce BoadaFundació ACE, Institut Català de Neurociències Aplicades, Facultat de Medicina, Universitat International de Catalunya-Barcelona, Barcelona, Spain.
Lucilla ParnettiSection of Neurology, Center for Memory Disturbances - Lab. of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Tomasz GabryelewiczDepartment of Neurodegenerative Disorders, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
Tormod FladbyDepartment of Neurology, Akershus University Hospital, Lorenskog, Norway.
José Luis MolinuevoAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Sylvia VilleneuveCentre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.
Jakub HortDepartment of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
Stéphane EpelbaumAP-HP, Hôpital de la Pitié Salpêtrière, Institute of Memory and Alzheimer's Disease (IM2A), Centre of excellence of neurodegenerative disease (CoEN), Department of Neurology, Paris, France.
Alberto LleóNeurology Department, Hospital de Sant Pau, Barcelona, Spain.
Sebastiaan EngelborghsVrije Universiteit Brussel, (VUB) Brussels, and University of Antwerp, Antwerp, Belgium.
Wiesje M van der FlierAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Susan LandauHelen Wills Neuroscience Institute, University of California, Berkeley, California, USA.
Julius PoppDepartment of Geriatric Psychiatry, Psychiatric University Hospital, Zürich, Switzerland.
Anders WallinCSIRO Health & Biosecurity, Parkville, Victoria, Australia.
Philip ScheltensAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Marcel Olde RikkertDepartment of Geriatric Medicine, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, The Netherlands.
Peter J SnyderInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Chris RoweDepartment of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia.
Gaël ChételatInstitut National de la Sant. et de la Recherche M.dicale (Inserm), Caen, France.
Agustin RuízFundació ACE, Institut Català de Neurociències Aplicades, Facultat de Medicina, Universitat International de Catalunya-Barcelona, Barcelona, Spain.
Marta MarquiéFundació ACE, Institut Català de Neurociències Aplicades, Facultat de Medicina, Universitat International de Catalunya-Barcelona, Barcelona, Spain.
Elena ChipiSection of Neurology, Center for Memory Disturbances - Lab. of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Steffen WolfsgruberGerman Center For Neurodegenerative Diseases/Clinical Research, Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE), Zentrum für klinische Forschung/AG, Cologne, Germany.
Michael HenekaDepartment of Neurodegenerative Diseases and Psychiatry, University Hospital Bonn, Bonn, Germany.
Henning BoeckerFunctional Neuroimaging Group, Department of Radiology, University Hospital Bonn, Bonn, Germany.
Oliver PetersKlinik für Psychiatrie und Psychotherapie, Charité Universitätsmedizin Berlin - CBF, Berlin, Deutschland.
Jonas JarholmDepartment of Neurology, Akershus University Hospital, Lorenskog, Norway.
Lorena RamiAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Adrià Tort-MerinoAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Alexa Pichet BinetteCentre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.
Judes PoirierCentre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.
Pedro Rosa-NetoCentre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.
Jiri CermanDepartment of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
Bruno DuboisAP-HP, Hôpital de la Pitié Salpêtrière, Institute of Memory and Alzheimer's Disease (IM2A), Centre of excellence of neurodegenerative disease (CoEN), Department of Neurology, Paris, France.
Marc TeichmannAP-HP, Hôpital de la Pitié Salpêtrière, Institute of Memory and Alzheimer's Disease (IM2A), Centre of excellence of neurodegenerative disease (CoEN), Department of Neurology, Paris, France.
Daniel AlcoleaNeurology Department, Hospital de Sant Pau, Barcelona, Spain.
Juan ForteaNeurology Department, Hospital de Sant Pau, Barcelona, Spain.
M Belén Sánchez-SaudinósNeurology Department, Hospital de Sant Pau, Barcelona, Spain.
Jarith EbenauAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Cornelia PocnetOld Age Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland.
Marie EckerströmInstitute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Louisa ThompsonInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Victor VillemagneDepartment of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia.
Rachel BuckleyBrigham and Women's Hospital and Department of Neurology Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Samantha BurnhamSection of Neurology, Center for Memory Disturbances - Lab. of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Marion DelarueInstitut National de la Sant. et de la Recherche M.dicale (Inserm), Caen, France.
Yvonne Freund-LeviDepartment of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Åsa K WallinDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden.
Inez RamakersAlzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Magda TsolakiMemory and Dementia Center, 3rd Department of Neurology, "G Papanicolau, " General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Hilkka SoininenInstitute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland.
Harald HampelGRC no 21, Alzheimer Precision Medicine (AMP), AP-HP, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
Luiza SpiruCarol DAVILA University of Medicine and Pharmacy, Bucharest, Romania.
Alzheimer's Disease Neuroimaging Initiative
FACEHBI study group
PREVENT-AD research group
Betty TijmsAlzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Rik OssenkoppeleAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Frans R J VerheyAlzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Frank JessenDepartment of Psychiatry, University of Cologne, Cologne, Germany.
Pieter Jelle VisserAlzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MCIHRNIA NIH HHS U01 AG024904
Abstract
introductionThe evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited.
methodsIn 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity.
resultsBetween cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. DISCUSSION: Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.
Indexed as
AmyloidosisCognitive DysfunctionAmyloidAmyloidogenic ProteinsApolipoprotein E4BiomarkersBrainHumansPositron-Emission TomographyAmyloidAmyloidogenic ProteinsApolipoprotein E4BiomarkersAlzheimer's diseaseamyloidcerebrospinal fluidpositron emission tomographysubjective cognitive decline
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.